4th Quarter - Report

AMERICAN SOCIETY OF HEMATOLOGY for AMERICAN SOCIETY OF HEMATOLOGY

Firm
Client
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2025 NIH funding FY 2025 AHRQ funding FY 2025 CDC funding FY 2025 funding for CDC Sickle Cell Data Collection program FY 2025 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2025 funding for Pediatric Specialty Loan Repayment Program (PSLRP, Public Health Service Act Sec. 775) FY 2025 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (H.R. 9029/S. 4942) Department of Defense Appropriations Act, 2025(H.R. 8774/S. 4921) FY 2025 Further Continuing Appropriations Act (through 3/14/2025)(H.R.10515, H.R. 10545)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Office of Management & Budget (OMB); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); SENATE; Centers For Disease Control & Prevention (CDC); Defense, Dept of (DOD)

Bills named: H.R. 9029 (118th), S. 4942 (118th), H.R. 8774 (118th), H.R. 10545 (118th), S. 4921 (118th), H.R. 10515 (118th)

Medical/Disease Research/Clinical Labs MED

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Open access policy for peer reviewed research journals Issues impacting blood supply shortages/safety Issues impacting delivery of bone marrow, peripheral blood, and cord blood Clinical trials regulations and coverage Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Advanced Research Projects Agency for Health (ARPA-H) White House Initiative on Womens Health Research re: priority research areas Issues impacting laboratory testing and pediatric reference intervals (PRIs) Issues impacting laboratory developed tests (LDTs) Issues impacting drug shortages House Energy and Commerce Committee proposed framework for NIH reform FDA guidance impacting hematology

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: SENATE; President of the U.S.; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Office of Management & Budget (OMB); White House Office

Medicare/Medicaid MMM

Coverage of blood transfusions under Medicare Hospice Benefit Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Strengthening Medicare for Patients and Providers Act (H.R. 2474) Resident Physician Shortage Reduction Act (S. 1302) CONNECT for Health Act (S. 2016/ H.R. 4189) Improving Access to Transfusion Care for Hospice Patients Act (S. 2186) Provider Reimbursement Stability Act of 2023 (H.R. 6371) Telehealth Modernization Act (H.R. 7623 / S. 3967) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097) dental coverage for Medicare beneficiaries CMS FY 2025 Hospice proposed rule and payment mechanisms for high intensity palliative care services, including blood transfusions Improving Seniors' Timely Access to Care Act (S. 4518/S. 4532/H.R. 8702) Senate Finance Committee Request for Information (RFI) on Medicare physician payment National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Duffy-null ICD-10 coding Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Senate draft Pay PCPs Act CY 2025 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule CY 2025 Physician Fee Schedule proposed rule

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Bills named: S. 2186 (118th), H.R. 2474 (118th), H.R. 8702 (118th), S. 2016 (118th), H.R. 6371 (118th), S. 4518 (118th), H.R. 4189 (118th), H.R. 7432 (118th), S. 3967 (118th), H.R. 7623 (118th), S. 5097 (118th), S. 1302 (118th), S. 4532 (118th)

Health Issues HCR

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097) FDA guidance impacting hematology

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 1297 (118th), H.R. 3024 (118th), S. 5226 (118th), H.R. 3884 (118th), S. 5097 (118th), H.R. 9872 (118th), H.R. 6301 (118th), S. 1423 (118th), H.R. 2907 (118th), H.R. 7432 (118th), S. 2039 (118th), H.R. 6746 (118th), S. 1852 (118th), H.R. 3100 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.